Today's guest is Ian Chan the co-founder and executive chairman of Abpro. Abpro is improving the lives of mankind facing severe and life-threatening diseases with next-generation antibody therapies. Ian explains how their technology is "future proofing" antibodies. 

Recently, Abpro announced its ABP 310 COVID antibody retains neutralization activity against the SARS-CoV-2 Omicron variant, which is exciting. 

You’ll hear the full story coming up but first some quick takeaways you’ll get from today’s conversation:

• How Abpro is cutting the time to generate antibodies for testing from 1 year to 2 months. 
• What all founders should focus on to facilitate fundraising - what Ian calls “first-class science”
• Unique challenges a company faces when it’s in high-growth mode and how to prepare. 

More about Ian he co-founded Abpro with his brother, Dr. Eugene Chan, who is the CEO. Not everyone goes into business with family but they’ve done it successfully a few times actually. Ian received an AB from Brown University and MBA from Harvard University.

Show notes:

https://abpro.com/

Abpro Reports Its ABP 310 COVID Antibody Retains Neutralization Activity Against the SARS-CoV-2 Omicron Variant

Qualio

Apply to be on the show: https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez

Qualio website:
https://www.qualio.com/

Previous episodes:
https://www.qualio.com/from-lab-to-launch-podcast

Apply to be on the show:
https://forms.gle/uUH2YtCFxJHrVGeL8

Music by keldez